SIR,-The publication of any paper intended to reduce the disparity between the theory and practice of (cancer) clinical trial design and analysis is to be wAelcomed. Stuart
Pocock's survey of the current practice of clinical trials (Br. J. Cancer (1978) 38, 757) indicates that studies involving insufficient subjects or using inappropriate methods of analysis are common. This will come as no surprise to many medical statisticians working in the field.
The "group sequential methods" w%Nhich he advocates represent a direct attempt to match theory to common practice. Further development of group sequential techniques for use with appropriate non-parametric methods of survival data analysis (such as the logrank test) would be welcome.
Unfortunately, in presenting his case for the use of group sequential methods, Dr Pocock seeks to demonstrate (p. 757) "a sharp contrast between the theoretical ideal of sequential methods and the practical situation of cancer clinical trials". Whilst strong assumptions may have been necessary for the valid application of (conventional) sequential methods at earlier stages in their development, more recent contributions have allowed considerable relaxation of these restrictions.
For example, Cox (1963) and Whitehead (1978) greatly extend the class of distributions to which sequential methods may be applied. and sequential forms of the logrank and Wilcoxon tests described by Jones and Whitehead (1979) do not require patients to be entered in matched pairs or patient evaluation to be instantaneous. Of course, if the delay before evaluation is not fairly short relative to the recruitment period of the trial, there will be insufficient feedback of trial progress to w-arrant use of any sequential method. Group sequential methods do assume a regular, rather than continuous, examination of the data, although only a very strict interpretation of conventional methods would render this a problem.
The calculations involved in the use of the sequential, logrank and Wilcoxon tests can be carried out using computer programs with 12 wihich many clinical trials organisers will already be familiar (for example by using the logrank program referred to by Peto et al., 1977 
